Rodrigo Vazquez Guillamet

Medicine & Life Sciences

1. Abatacept 7%
2. Allografts 6%
3. Anti-Bacterial Agents 8%
4. Antilymphocyte Serum 6%
5. Bacteremia 8%
6. Candida 6%
7. Candidemia 7%
8. Cefepime 7%
9. Chronic Bronchitis 12%
10. Chronic Obstructive Pulmonary Disease 39%
11. Clinical Decision Rules 7%
12. Cohort Studies 9%
13. Comorbidity 7%
14. Coronavirus 6%
15. Critical Care 6%
16. Critical Illness 7%
17. Ehrlichiosis 7%
18. Extravascular Lung Water 7%
19. Hamman-Rich Syndrome 8%
20. Healthcare-Associated Pneumonia 7%
21. Hospital Rapid Response Team 8%
22. Infections 17%
23. Interleukin-6 Receptors 7%
24. Interstitial Lung Diseases 7%
25. Lung 64%
26. Lung Transplantation 100%
27. Meropenem 6%
28. Mortality 20%
29. Obstructive Lung Diseases 7%
30. Pneumonia 6%
31. Primary Graft Dysfunction 16%
32. Pseudomonas 6%
33. Septic Shock 6%
34. Skilled Nursing Facilities 6%
35. Smokers 10%
36. Survival 9%
37. Tazobactam Drug Combination Piperacillin 7%
38. Terminal Care 7%
39. Therapeutics 6%
40. Thorax 7%
41. Tissue and Organ Procurement 6%
42. Tissue Donors 31%
43. Tobacco Products 6%
44. tocilizumab 9%
45. Tomography 7%
46. Total Lung Capacity 7%
47. Transplant Recipients 21%
48. Transplantation 11%
49. Transplants 25%
50. Water-Electrolyte Balance 6%